ATAI Life Sciences NV reports results for the quarter ended in December - Earnings Summary

• ATAI Life Sciences NV ATAI reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of seven analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -19 cents to -14 cents per share.

• Revenue fell 52.6% to $18.00 thousand from a year ago; analysts expected $187.60 thousand.

• ATAI Life Sciences NV's reported EPS for the quarter was a loss of 12 cents​.

• The company reported a quarterly loss of $18.29 million.

• ATAI Life Sciences NV shares had risen by 27.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for ATAI Life Sciences NV is $11.00

This summary was machine generated from LSEG data March 28 at 12:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)